Celldex Therapeutics CLDX Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Celldex Therapeutics's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Celldex Therapeutics's total liabilities?
- Celldex Therapeutics (CLDX) reported total liabilities of $55.03M in Q1 2026.
- How has Celldex Therapeutics's total liabilities changed year-over-year?
- Celldex Therapeutics's total liabilities increased by 50.8% year-over-year, from $36.49M to $55.03M.
- What is the long-term trend for Celldex Therapeutics's total liabilities?
- Over 5 years (2020 to 2025), Celldex Therapeutics's total liabilities has grown at a 16.1% compound annual growth rate (CAGR), from $26.48M to $55.82M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.